이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Clinical Evaluation of Hearing Aid OTC Self-Assessment Methods for Adults With Perceived Mild-to-Moderate Hearing Loss

2026년 7월 30일 업데이트: Rehear Audiology Company LTD

Clinical Evaluation of Two Rehear RH210 Self-Assessment Methods for Generating NAL-R-Based Prescribed Gain Compared With Conventional Audiometry in Adults With Perceived Mild-to-Moderate Hearing Loss

The goal of this clinical trial is to compare two methods of self assessment of hearing with conventional audiometry in an OTC Hearing Aid for adults with perceived mild to moderate hearing loss. The main questions it aims to answer are:

  1. To evaluate agreement between prescribed gain outputs generated from conventional audiometry and those generated from the self-assessment response method.
  2. Determine whether either self-assessment response method provides acceptable estimated audibility.
  3. Evaluate participant preference between the detection response method and the audibility-release response method.

Researchers will compare the two novel methods with conventional audiometry to determine levels of agreement.

Participants will self assess their hearing methods using two novel methods of hearing assessment as well as receive a conventional audiometric evaluation of hearing levels.

연구 개요

상세 설명

The purpose of this clinical investigation is to evaluate two RH210 hearing aid software self-assessment response methods used to generate NAL-R-based prescribed gain for adults with perceived mild-to-moderate hearing loss. The study will compare prescribed gain outputs derived from each RH210 self-assessment response method with prescribed gain outputs derived from conventional audiometry using the same NAL-R prescription approach. The study will also assess whether the resulting prescribed gain provides estimated audibility using Speech Intelligibility Index (SII) analysis, and will evaluate participant preference between the two self-assessment response methods. The RH210A is an air-conduction hearing aid designed for adults with perceived mild-to-moderate sensorineural hearing loss.

The two RH210 self-assessment response methods evaluated in this study are:

  1. Detection response method (Option 1): the participant presses a response control when they hear the tone or beep.
  2. Audibility-release response method (Option 2): the participant maintains a press while the tone or beep is audible and releases the response control when they no longer hear it.

The study is designed to:

  1. Evaluate agreement between NAL-R prescribed gain outputs generated from conventional audiometry and NAL-R prescribed gain outputs generated from each RH210 self-assessment response method.
  2. Compare the detection response method and audibility-release response method with respect to prescribed gain agreement by ear and frequency.
  3. Assess estimated audibility associated with the self-assessment-derived NAL-R prescriptions using Speech Intelligibility Index (SII) analysis.
  4. Determine whether either self-assessment response method provides acceptable estimated audibility, including in cases where prescribed gain does not exactly match the conventional-audiometry-derived NAL-R prescription.
  5. Evaluate participant preference between the detection response method and the audibility-release response method.
  6. Assess general agreement, completeness, invalid-test rate, usability and response consistency for each self-assessment response method.
  7. Support validation of the Rehear assessment-to-fitting pathway without positioning the RH210 self-assessment function as a diagnostic audiometer.

This study is not intended to establish Human Factors performance. However, observations arising during execution of the assessment workflow may identify opportunities to improve the user interface, workflow or user guidance before the final Human Factors validation study. These observations are exploratory development outputs and are not formal study endpoints.

연구 유형

중재적

등록 (추정된)

24

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

  • 이름: Sanna Hou, Master of Audiology
  • 전화번호: +61 2 9412 6872
  • 이메일: sann.hou@nal.gov.au

연구 장소

    • New South Wales
      • Macquarie Park, New South Wales, 호주, 2113
        • National Acoustic Laboratories
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

아니

설명

Inclusion Criteria:

  • Age 18 years
  • Self-perceived mild-to-moderate hearing difficulties/ hearing loss
  • Competent smartphone use (able to complete self-fitting via the app)
  • Able and willing to provide informed consent
  • HHIA screening consistent with perceived hearing difficulty
  • Willingness and ability to attend two in-person research appointments
  • Ability to operate a SmartPhone

Exclusion Criteria:

  • Conductive or mixed hearing loss
  • Occluding cerumen
  • Otologic disease/ active ear pathology
  • Severe or profound hearing loss (PTA >S0dBHL) (WHO, 2021)
  • Presence of (red-flag) conditions relevant to OTC hearing aid use (per 21 CFR 801.421)
  • Visible deformity of the ear (congenital or traumatic).
  • Fluid, pus, or blood coming from the ear (e.g., active drainage).
  • Sudden or rapidly progressive hearing loss within the recent past (often defined as within ~90 days).
  • Any acute or chronic dizziness or vertigo associated with hearing issues.
  • Pain or discomfort in or around the ear.
  • Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
  • Unilateral hearing loss of sudden onset or large asymmetry between ears.
  • Audiometric air-bone gap suggestive of possible conductive pathology (e.g., gap equal or more than 15 dB at key frequencies)
  • Visible evidence of significant cerumen (ear wax) accumulation or foreign body in the ear canal.
  • Unilateral hearing loss of sudden onset or large asymmetry between ears

Exclusion Criteria:

-

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 크로스오버 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
활성 비교기: Conventional manual pure-tone audiometry
The comparator for this clinical investigation is conventional manual pure-tone audiometry performed in accordance with ANSI/ASA S3.21-2004 (R2023), Methods for Manual Pure-Tone Threshold Audiometry, followed by generation of a NAL-R-based prescribed gain output.
실험적: Mode A
RH210 self-test method 1: detection response method, where the participant presses when they hear the tone or beep

The Investigational Medical Device (IMD) consists of the RH210 hearing aid software self-test function accessed through the Rehear smartphone application and used in combination with the RH210A compatible in-ear hardware platform.

For this clinical investigation, the RH210A hardware platform is used to present calibrated test sounds (pure tones) to the participant during the app-based self-test. The RH210A is not being evaluated as a diagnostic audiometer, and the study is not designed to evaluate the hearing aid's amplification performance.

The two RH210 self-test response methods evaluated in this study are:

  • Detection response method: the participant presses the response control when they hear the tone or beep (Mode A).
  • Audibility-release response method: the participant maintains the response control while the tone or beep is audible and releases the response control when they no longer hear the tone or beep (Mode B).
실험적: Mode B
RH210 self-test method 2: audibility-release response method, where the participant releases the response control when they no longer hear the tone or beep

The Investigational Medical Device (IMD) consists of the RH210 hearing aid software self-test function accessed through the Rehear smartphone application and used in combination with the RH210A compatible in-ear hardware platform.

For this clinical investigation, the RH210A hardware platform is used to present calibrated test sounds (pure tones) to the participant during the app-based self-test. The RH210A is not being evaluated as a diagnostic audiometer, and the study is not designed to evaluate the hearing aid's amplification performance.

The two RH210 self-test response methods evaluated in this study are:

  • Detection response method: the participant presses the response control when they hear the tone or beep (Mode A).
  • Audibility-release response method: the participant maintains the response control while the tone or beep is audible and releases the response control when they no longer hear the tone or beep (Mode B).

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Agreement of NAL-R prescribed gain outputs (dB) between the comparator conditions
기간: Day 1

The primary endpoint is the agreement of NAL-R prescribed gain outputs (dB), by ear (R/L) and frequency (Hz), between:

  • Conventional-audiometry-derived NAL-R prescribed gain (dB), and
  • RH210 self-test-derived NAL-R prescribed gain (dB), generated using each of the two RH210 response methods.

The frequency-specific analysis will include: 500 Hz; 1 kHz; 2 kHz; and 4 kHz.

The two RH210 response methods are:

  • Detection response method: participant presses when they hear the tone or beep (Mode A).
  • Audibility-release response method: participant releases the response control when they no longer hear the tone or beep Mode B).
Day 1

2차 결과 측정

결과 측정
측정값 설명
기간
Number of Participants with Treatment-Related Adverse Events as classified by ISO14155:2026
기간: Day 1

The secondary safety objective is to assess the safety of participant exposure to the RH210 app-based self-test procedure when the RH210A in-ear hardware platform is used to present test sounds.

Safety will be assessed by the incidence, severity, seriousness and relationship to the investigational device or study procedure of:

  • adverse events;
  • adverse device effects;
  • anticipated adverse device effects;
  • discomfort associated with in-ear device use;
  • excessive loudness or sound intolerance;

No formal statistical hypothesis is proposed for safety. Safety outcomes will be summarized descriptively.

Day 1
Difference in Speech Intelligibility Index (SII) and SRT in quiet (CNC words) between the three conditions
기간: Day 1

The secondary objective is to evaluate whether RH210 self-test-derived NAL-R prescribed gain outputs (dB) provide estimated audibility comparable to the conventional-audiometry-derived NAL-R reference pathway.

The secondary endpoint is the difference in Speech Intelligibility Index / Audibility Index and SRT in quiet between:

(1) The conventional-audiometry-derived NAL-R prescribed gain condition (dB); and (2) Each RH210 self-test-derived NAL-R prescribed gain (dB) condition.

The analysis will be conducted under a pre-specified standard aided speech condition (SRT50% dB), for example adaptive speech in quiet SRT50, with the final method defined in the Statistical Analysis Plan

Day 1

기타 결과 측정

결과 측정
측정값 설명
기간
Participant preference (A vs B questionnaire) will be assessed after completion of both self fit response methods.
기간: Day 1

The first exploratory objective is to evaluate participant preference between the two RH210 self-test response methods.

Participant preference will be assessed after completion of both RH210 response methods. The endpoint will include:

  • proportion of participants preferring the detection response method;
  • proportion preferring the audibility-release response method;
  • proportion reporting no preference;
  • reasons for preference, where collected. No formal hypothesis is proposed. Results will be summarized descriptively.
Day 1
Compare the practical performance of the two RH210 self-test response methods using NAL checklist.
기간: Day 1

Exploratory endpoints will include, for each response method:

  • completion rate;
  • invalid or unusable test rate;
  • missing frequency-specific data rate;
  • test duration;
  • participant-reported ease of use;
  • observed difficulty or need for clarification;
  • repeatability or response consistency, where repeat data are available.

No formal hypothesis is proposed. Results will be summarized descriptively.

Day 1

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

수사관

  • 수석 연구원: Bettina Turnbull, Doctor of Audiology, National Acoustic Laboratories

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 8월 15일

기본 완료 (추정된)

2026년 10월 1일

연구 완료 (추정된)

2026년 10월 1일

연구 등록 날짜

최초 제출

2026년 7월 26일

QC 기준을 충족하는 최초 제출

2026년 7월 26일

처음 게시됨 (실제)

2026년 7월 31일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 8월 3일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 7월 30일

마지막으로 확인됨

2026년 7월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

IPD 계획 설명

The study is a commercial sponsor investigation of a product that is not yet cleared by regulatory agencies

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다